EL7.AI
StocksMedium•18 November 2026•
1 min read

Biogen and Eisai LEADER Study Shows LEQEMBI Slows Alzheimer's Progression

Key Facts

1Biogen and Eisai released LEADER study data showing LEQEMBI significantly reduces the rate of progression to moderate or severe Alzheimer's disease dementia.

Biogen and Eisai released LEADER study data showing LEQEMBI significantly reduces the rate of progression to moderate or severe Alzheimer's disease dementia. Benzinga reported that the companies provided these three-year real-world findings to support the long-term efficacy of the treatment in slowing disease advancement.

Biogen shares closed at $250.79 on November 17, 2026, while Eisai, trading under the ticker 4523.T, closed at 5240 yen on November 18, 2026. The positive clinical results reinforce the therapeutic profile of the drug as the companies continue to establish its long-term clinical evidence in the market.

Open on chart